Indications for: DETECTNET
Use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults.
See full labeling. Prep patient accordingly. Use within 2hrs after calibration time. Administer 148MBq (4mCi) as IV inj over approx. 1min, followed by an IV flush of NaCl 0.9% inj. Begin image acquisition 45–90mins after inj.
Should be administered by experienced physicians who are qualified in the use of radionuclides. Must handle with appropriate safety measures to minimize radiation exposure. Radiation risk. Advise patients to hydrate before and after inj, and to void frequently after administration. Risk for image misinterpretation; increased uptake may be seen in other pathologic conditions (eg, thyroid disease, subacute inflammation) or as normal physiologic variant (eg, uncinate process of the pancreas). Hepatic or renal impairment. Elderly. Pregnancy: exclude status prior to administration. Nursing mothers: interrupt breastfeeding for 12hrs after administration.
Radioactive diagnostic agent.
Concomitant with long-acting somatostatin analogs: wash-out period of 28 days is recommended prior to imaging. Concomitant with short-acting somatostatin analogs: wash-out period of 2 days is recommended prior to imaging.
Nausea, vomiting, flushing; hypersensitivity reactions.
Generic Drug Availability: